Reading the tape
NASDAQ: SYBX
Synlogic, Inc.
Healthcare · Biotechnology
Market Cap
$6.97M
52w High
$1.96
52w Low
$0.54
P/E
-7.30
Volume
3.18K
Outstanding Shares
11.70M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -49.06%Revenue (TTM): -100%FCF (TTM): 86.24%
What changed
The stock fell 49.06% over the last year. Revenue declined 100% over the trailing twelve months. Free cash flow grew 86.24% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive move in revenue — currently down 100% — would be the clearest signal to resolve the ambiguity.
Company profile
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States.
CEOMary Beth Dooley
SectorHealthcare
IndustryBiotechnology
Employees1
IPO dateSep 30, 2015
Valuation
Forward P/E—
EV/EBITDA0.25
Enterprise value-$878.66K
Stock splits
Sep 28, 2023↓ Reverse
Every 15 shares became 1
Aug 28, 2017↓ Reverse
Every 7 shares became 1
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-8.47%▲95.38%vs FY2024
Analyst consensus
RatingBuy
Target price—
10
Buy
3
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 6, 2026
Q2 FY26 · EPS est — · Revenue est —
View